Abstract: The present invention relates to a hybrid Hepatocyte Growth Factor (HGF) gene which is prepared by inserting an inherent or foreign intron between exons 4 and 5 in HGF cDNA, which has a base sequence of SEQ ID NO: 2. The gene has high expression efficiency and simultaneously expresses two heterotypes of HGF and dHGF (deleted variant HGF). Further the gene may be used for treating or preventing ischemic or liver diseases.
Type:
Grant
Filed:
December 31, 2009
Date of Patent:
June 29, 2010
Assignee:
Viromed Co., Ltd.
Inventors:
Jong-Mook Kim, Woong Hahn, Eun-Jin Park
Abstract: The present invention relates to a hybrid Hepatocyte Growth Factor (HGF) gene which is prepared by inserting an inherent or foreign intron between exons 4 and 5 in HGF cDNA, which has a base sequence of SEQ ID NO: 2. The gene has high expression efficiency and simultaneously expresses two heterotypes of HGF and dHGF (deleted variant HGF). Further the gene may be used for treating or preventing ischemic or liver diseases.
Type:
Application
Filed:
December 31, 2009
Publication date:
April 29, 2010
Applicant:
ViroMed Co., Ltd.
Inventors:
Jong-Mook Kim, Woong Hahn, Eun-Jin Park
Abstract: The present invention relates to compositions and methods for fusion protein separation utilizing a peptide linker comprising a novel thrombin cleavage site.
Type:
Grant
Filed:
April 20, 2006
Date of Patent:
September 8, 2009
Assignee:
ViroMed Co., Ltd.
Inventors:
Sujeong Kim, Jong-Mook Kim, Song Shan Xu
Abstract: The present invention relates to the use of internal promoters in mammalian expression vectors including plasmid vectors and enhancer-deleted retroviral vectors. The retroviral vectors have improved safety and optimal levels of transgene expression and vector titers.
Abstract: The present invention relates to the compositions for a gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof. More specifically, the present invention provides a gene therapy of rheumatoid arthritis by preparing a recombinant vector that expresses a gene encoding an anti-angiogenic protein such as angiostatin or parts thereof, and transplanting the recombinant vector or a cell that is transfected or transduced with the recombinant vector into the affected area of a patient, and also provides the compositions for the gene therapy. The compositions for the gene therapy according to the present invention can be used effectively for the treatment of rheumatoid arthritis, for which effective treating methods have not been developed until now, by providing the anti-angiogenic proteins into the knee of a patient continuously to prevent the synovial tissue hyperplasia and the resulting inflammation.
Type:
Grant
Filed:
January 3, 2002
Date of Patent:
February 13, 2007
Assignee:
Viromed Co., Ltd.
Inventors:
Jong-Mook Kim, Seong-Hyun Ho, Eun-Jin Park, Sunyoung Kim
Abstract: The present invention relates to the compositions for a gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof. More specifically, the present invention provides a gene therapy of rheumatoid arthritis by preparing a recombinant vector that expresses a gene encoding an anti-angiogenic protein such as endostatin or parts thereof, and transplanting the recombinant vector or a cell that is transfected or transduced with the recombinant vector into the affected area of a patient, and also provides the compositions for the gene therapy. The compositions for the gene therapy according to the present invention can be used effectively for the treatment of rheumatoid arthritis, for which effective treating methods have not been developed until now, by providing the anti-angiogenic proteins into the knee of a patient continuously to prevent the synovial tissue hyperplasia and the resulting inflammation.
Type:
Application
Filed:
May 11, 2006
Publication date:
September 7, 2006
Applicant:
ViroMed Co., Ltd.
Inventors:
Jong-Mook Kim, Seong-Hyun Ho, Eun-Jin Park, Sunyoung Kim
Abstract: The present invention relates to the compositions for a gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof. More specifically, the present invention provides a gene therapy of rheumatoid arthritis by preparing a recombinant vector that expresses a gene encoding an anti-angiogenic protein such as platelet factor-4 or parts thereof, and transplanting the recombinant vector or a cell that is transfected or transduced with the recombinant vector into the affected area of a patient, and also provides the compositions for the gene therapy. The compositions for the gene therapy according to the present invention can be used effectively for the treatment of rheumatoid arthritis, for which effective treating methods have not been developed until now, by providing the anti-angiogenic proteins into the knee of a patient continuously to prevent the synovial tissue hyperplasia and the resulting inflammation.
Type:
Application
Filed:
May 11, 2006
Publication date:
August 31, 2006
Applicant:
ViroMed Co., Ltd.
Inventors:
Jong-Mook Kim, Seong-Hyun Ho, Eun-Jin Park, Sunyoung Kim
Abstract: The present invention provides a safe and highly efficient retroviral vector derived from the MLV (murine leukemia virus) for use in gene therapy, which lacks viral coding sequences but contains the genetically engineered EF I? non-coding sequence harboring splicing acceptor.
Type:
Grant
Filed:
September 8, 2001
Date of Patent:
May 23, 2006
Assignee:
ViroMed Co., Ltd.
Inventors:
Sun-Young Kim, Seung-Shin Yu, Jun-Tae Lee